替考拉宁治疗G^+菌感染的疗效和安全性  

Clinical evaluation of teicoplanin in treatment of gram-positive bacterial infections

作　　者：张天托[1] 黄树灿[1] 周凤丽[1] 饶宪[1] 张扣兴[1] 文博[1] 唐英春[1] 

机构地区：[1]中山大学附属第三医院,广州510630

出　　处：《中国新药杂志》2003年第12期1041-1043,共3页Chinese Journal of New Drugs

摘　　要：目的:评价替考拉宁治疗G^+菌感染的疗效和安全性。方法:采用随机对照及开放试验,以万古霉素为对照。完成病例60例,其中试验组30例,替考拉宁0.2～0.4g,qd,静脉滴注;对照组30例,万古霉素0.5g,tid,静脉滴注。疗程均为7～14d。结果:试验组痊愈率、有效率、细菌清除率分别为50％,80％和83.3％,对照组分别为46.7％,76.7％和76.7％,2组差异无显著性。不良反应发生率分别为10％和13.3％,2组差异亦无显著性。结论:替考拉宁治疗G^+菌感染安全有效。Objective:To study the safety and efficacy of teicoplanin in treatment of gram-positive bacterial infections. Methods: In the randomized, controlled and opened clinical trial, 60 patients were equally divided to receive once daily dose of 0.2-0.4g teicoplanin given by infusion for 7-14d or 3 times daily dose of 0. 5g intravenous vancomycin for 7-14d. Results:The cure rate, total effective rate and bacterial clearance rate were 50 % , 80 % , and 83.3% respectively for teicoplanin group and were 46.7% ,76.7% and 76.7% respectively for control group. 10% adverse drug reactions occurred in teicoplanin group and 13.3% in vancomycin group.Conclusion:Teicoplanin seems to be a highly effective and safe agent for treatment of gram-positive bacterial infections.

关 键 词：替考拉宁 万古霉素 G^+菌 

分 类 号：R978.16[医药卫生—药品] R969.4[医药卫生—药学]